Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1982 1
1990 1
1995 1
2002 1
2004 2
2005 1
2006 2
2007 2
2008 1
2009 3
2010 3
2011 1
2012 2
2014 1
2015 3
2018 1
2019 2
2020 2
2021 2
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

30 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Early progressive calcific cardiac valvular disease"
Page 1
Detecting native and bioprosthetic aortic valve disease using (18)F-sodium fluoride: Clinical implications.
Fletcher AJ, Dweck MR. Fletcher AJ, et al. J Nucl Cardiol. 2021 Apr;28(2):481-491. doi: 10.1007/s12350-020-02411-x. Epub 2020 Nov 11. J Nucl Cardiol. 2021. PMID: 33175301 Free PMC article. Review.
Calcific aortic valve disease is the most common valvular disease and confers significant morbidity and mortality. There are currently no medical therapies that successfully halt or reverse the disease progression, making surgical …
Calcific aortic valve disease is the most common valvular disease and confers significant morbidity and m …
Lipid Interventions in Aortic Valvular Disease.
Choi KJ, Tsomidou C, Lerakis S, Madanieh R, Vittorio TJ, Kosmas CE. Choi KJ, et al. Am J Med Sci. 2015 Oct;350(4):313-9. doi: 10.1097/MAJ.0000000000000544. Am J Med Sci. 2015. PMID: 26263237 Review.
Aortic valve stenosis is the most common valvular disease in the elderly population. ...The pathogenesis of AS shares many similarities to that of atherosclerosis; therefore, it was hypothesized that certain lipid interventions could prevent or slow the pr …
Aortic valve stenosis is the most common valvular disease in the elderly population. ...The pathogenesis of AS shares m …
Pharmacotherapy of aortic stenosis-success or failure?
Dimitrow PP, Jawien M, Rajtar-Salwa R. Dimitrow PP, et al. Curr Pharm Biotechnol. 2012 Oct;13(13):2497-502. doi: 10.2174/138920112804583096. Curr Pharm Biotechnol. 2012. PMID: 22280424 Review.
Aortic stenosis (AS) is a degenerative valvular disease that has, until recently, been considered to be a progressive and the most importantly unmodifiable process. ...Targeted drug therapy to prevent the progression of calcific AS disease …
Aortic stenosis (AS) is a degenerative valvular disease that has, until recently, been considered to be a progressive a …
Lp(a) in the Pathogenesis of Aortic Stenosis and Approach to Therapy with Antisense Oligonucleotides or Short Interfering RNA.
Di Costanzo A, Indolfi C, Franzone A, Esposito G, Spaccarotella CAM. Di Costanzo A, et al. Int J Mol Sci. 2023 Oct 6;24(19):14939. doi: 10.3390/ijms241914939. Int J Mol Sci. 2023. PMID: 37834387 Free PMC article. Review.
Several drugs have been tested to reduce low-density lipoprotein (LDL) and lipoprotein(a) (Lp(a)) levels, inflammation, and calcification. The Proprotein Convertase Subtilisin/Kexin type 9 inhibitors (PCSK9-i) could decrease the progression of aortic stenosis and th …
Several drugs have been tested to reduce low-density lipoprotein (LDL) and lipoprotein(a) (Lp(a)) levels, inflammation, and calcification …
Medical therapy for rheumatic heart disease: is it time to be proactive rather than reactive?
Rajamannan NM, Antonini-Canterin F, Moura L, Zamorano JL, Rosenhek RA, Best PJ, Lloyd MA, Rocha-Goncalves F, Chandra S, Alfieri O, Lancellotti P, Tornos P, Baliga RR, Wang A, Bashore T, Ramakrishnan S, Spargias K, Shuvy M, Beeri R, Lotan C, Suwaidi JA, Bahl V, Pierard LA, Maurer G, Nicolosi GL, Rahimtoola SH, Chopra K, Pandian NG. Rajamannan NM, et al. Indian Heart J. 2009 Jan-Feb;61(1):14-23. Indian Heart J. 2009. PMID: 19729684 Free PMC article. Review.
The potential for statin therapy in slowing the progression of valvular heart disease is still controversial. Retrospective studies have shown that medical therapy is beneficial for patients with calcific aortic stenosis and recently for rheumat …
The potential for statin therapy in slowing the progression of valvular heart disease is still controversial. Re …
The Pathogenesis and treatment of the valvulopathy of aortic stenosis: Beyond the SEAS.
Elmariah S, Mohler ER 3rd. Elmariah S, et al. Curr Cardiol Rep. 2010 Mar;12(2):125-32. doi: 10.1007/s11886-010-0089-6. Curr Cardiol Rep. 2010. PMID: 20425167 Free PMC article. Review.
However, two randomized trials, SALTIRE and the SEAS study, showed no benefit with statin therapy for AS. These results have shed doubt over the efficacy of statin therapy for AS, although their potential efficacy at early stages of aortic valve disease …
However, two randomized trials, SALTIRE and the SEAS study, showed no benefit with statin therapy for AS. These results have shed dou …
Prevention of calcific aortic valve stenosis-fact or fiction?
Cawley PJ, Otto CM. Cawley PJ, et al. Ann Med. 2009;41(2):100-8. doi: 10.1080/07853890802331394. Ann Med. 2009. PMID: 18720096 Review.
Valve replacement is the only long-term effective treatment for calcific aortic valve stenosis. ...In addition, we need to define the optimal timing and duration of therapy for this chronic slowly progressive disease; treatments aimed at the …
Valve replacement is the only long-term effective treatment for calcific aortic valve stenosis. ...In addition, we need …
Lipoprotein(a) is robustly associated with aortic valve calcium.
Kaiser Y, Singh SS, Zheng KH, Verbeek R, Kavousi M, Pinto SJ, Vernooij MW, Sijbrands EJG, Boekholdt SM, de Rijke YB, Stroes ESG, Bos D. Kaiser Y, et al. Heart. 2021 Sep;107(17):1422-1428. doi: 10.1136/heartjnl-2021-319044. Epub 2021 May 7. Heart. 2021. PMID: 33963048 Free PMC article.
In the Rotterdam Study cohort, higher Lp(a) concentrations were also associated with increase in aortic valve Agatston score (beta 0.19, 95% CI 0.06 to 0.32 per 50 mg/dL increase). ...These results provide further rationale to assess the effect of Lp(a) lowering interventi …
In the Rotterdam Study cohort, higher Lp(a) concentrations were also associated with increase in aortic valve Agatston score (beta 0. …
Causes and Clinical Outcomes of Patients Who Are Ineligible for Transcatheter Mitral Valve Replacement.
Niikura H, Gössl M, Kshettry V, Olson S, Sun B, Askew J, Stanberry L, Garberich R, Tang L, Lesser J, Bae R, Harris KM, Bradley SM, Sorajja P. Niikura H, et al. JACC Cardiovasc Interv. 2019 Jan 28;12(2):196-204. doi: 10.1016/j.jcin.2018.10.042. JACC Cardiovasc Interv. 2019. PMID: 30678799 Free article.
Thus far, no investigation has examined ineligible patients and their clinical outcomes. METHODS: A total of 203 patients (mean age 79 9 years, 48% men) who were ineligible for participation in early feasibility studies of TMVR were examined. ...Patients not eligibl …
Thus far, no investigation has examined ineligible patients and their clinical outcomes. METHODS: A total of 203 patients (mean age 7 …
The mitral pulmonary autograft: assessment at midterm.
Kabbani SS, Jamil H, Hammoud A, Hatab JA, Nabhani F, Hariri R, Sabbagh N, Ross D. Kabbani SS, et al. Ann Thorac Surg. 2004 Jul;78(1):60-5; discussion 65-6. doi: 10.1016/S0003-4975(03)01657-6. Ann Thorac Surg. 2004. PMID: 15223403 Review.
BACKGROUND: There is a dire need, especially in emergent societies, for a mitral substitute that does not require anticoagulation, and is not affected by early degeneration. METHODS: Between 1997 and 2003, 80 patients had successful mitral valve replacement with a p …
BACKGROUND: There is a dire need, especially in emergent societies, for a mitral substitute that does not require anticoagulation, and is no …
30 results